meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
aurora kinase inhibitors
alisertib plus paclitaxel
biguanide
metformin
celecoxib plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus fulvestrant
dalpiciclib plus fulvestrant
palbociclib based treatment
palbociclib plus fulvestrant
ribociclib based treatment
ribociclib plus endocrine therapy
ribociclib plus fulvestrant
HDAC inhibitor
entinostat plus exemestane
tucidinostat based treatment
tucidinostat plus exemestane
IGF-1R inhibitors
ganitumab plus endocrine therapy
Immunostimulant
vaccine
OBI-822/OBI-821 plus cyclophosphamide
mTOR inhibitors
sapanisertib plus fulvestrant
phosphoinositide 3-kinase (PI3K) inhibitor
alpelisib based treatment
alpelisib plus fulvestrant
buparlisib based treatment
buparlisib plus fulvestrant
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs taxanes
vs paclitaxel
vs endocrine therapy
vs exemestane
vs fulvestrant
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
ribociclib based treatment
ribociclib plus endocrine therapy
ribociclib plus fulvestrant
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
Comparator:
vs endocrine therapy;
vs fulvestrant;
Risk of bias:
low;
some concerns;
high;
NA;